NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
Updated: May 25, 2022
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent
Sponsor
ClinicalTrials.gov Identifier: NCT04942067
Official Title: A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis
First Posted: June 28, 2021
Click here for details on ClinicalTrials.gov
Drug: APG-2575+ Pd
Drug: APG-2575 + DRd
Lisaftoclax (Code C156249)
APG 2575
APG-2575
APG2575
Bcl-2 Inhibitor APG 2575
Lisaftoclax
LISAFTOCLAX
Locations
United States, Florida
United States, New York
United States, Ohio